Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery.

OBJECTIVE

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently treated with the Janus kinase (JAK) inhibitor ruxolitinib. Perioperative management of ruxolitinib presents a clinical dilemma. Continued therapy may increase the risk of infection, cytopenia, and impaired wound healing during major surgery, whereas abrupt discontinuation can precipitate ruxolitinib discontinuation syndrome (RDS), an inflammatory rebound syndrome that may be life-threatening. Currently, there are no established perioperative guidelines for the management of ruxolitinib.

METHODS

We report a case of a 65-year-old patient with PMF undergoing elective coronary artery bypass graft (CABG) surgery.

RESULTS

Following multidisciplinary discussion with the haematology, ruxolitinib was withheld for 48 hours perioperatively and prophylactic corticosteroids were administered. The patient underwent an uncomplicated surgery and recovery without evidence of infection, thrombocytopaenia, or RDS.

CONCLUSION

This case highlights the challenges associated with perioperative ruxolitinib management and emphasises the importance of multidisciplinary decision-making and individualized risk assessment. Reporting such cases contributes to the limited literature on guiding perioperative management of JAK inhibitor therapy in patients undergoing major surgery.